No CrossRef data available.
Article contents
Creatine kinase levels during treatment with atypical antipsychotic agents
Published online by Cambridge University Press: 16 April 2020
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
- Type
- Posters, Tuesday, 7 May 2002
- Information
- Copyright
- Copyright © Elsevier, Paris 2002
References
(1)Boot, Ede Haan, LMassive increase in serum creatine kinase during olanzapine and quetiapine treatment, but not during treatment with clozapine. Psychopharmacology (Berl) 2000; 150:347–8CrossRefGoogle Scholar
(2)Meltzer, HYSerum creatine phosphokinase in schizophrenia. Am J Psychiatry 1976;133:192–197.Google Scholar
(3)Meltzer, HYSkeletal muscle necrosis following membraneactive drugs plus serotonin. J Neurol Sci 1976;28:41–56CrossRefGoogle ScholarPubMed
(4)Meltzer, HYRoss-Stanton, JSchlessinger, S.Mean serum creature kinase activity in patients with functional psychoses. Arch Gen Psychiatry 1980;37:650–655.CrossRefGoogle Scholar
(5)Meltzer, HYCola, PAParsa, MMarked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology 1996;15:395–405CrossRefGoogle ScholarPubMed
(6)Meltzer, HYMassive serum creatine kinase increases with atypical antipsychotic drugs: what is the mechanism and the message? Psychopharmacology (Berl) 2000;150:349–50.CrossRefGoogle ScholarPubMed
(7)Reznik, IVolchek, LMester, RKotler, MSpivak, BWeizman, A et al. Myotoxicity and neurotoxicity during clozapine treatment. Clin Neuropharmacol 2000;23:276–80CrossRefGoogle ScholarPubMed
(8)Scelsa, SNSimpson, DMMcQuiston, HL et al. Clozapineinduced myotoxicity in patients with chronic psychotic disorders. Neurology 1996;47:1518–1523.CrossRefGoogle Scholar
You have
Access
Comments
No Comments have been published for this article.